JPT/PepMix™ Human (Kir4.1)/PMKir4.1/

PepMix™Human(Kir4.1)

ProductCode:PM-Kir4.1

Poolof92peptidesderivedfromapeptidescan(15merswith11aaoverlap)throughKir4.1(ATP-sensitiveinwardrectifierpotassiumchannel10,UniProtID:P78508)ofHomosapiens(Human).
Amount:1vialcontaining15nmol(appr.25µg)perpeptide
Purity:>70%(HPLC-MS)
DeliveryFormat:Freezedriedinambertypeglassvial
Application(s):T-cellassays,Immunemonitoring,AntigenspecificT-cellstimulation,T-cellexpansion,Cellularimmuneresponse,ELISPOT,ICS,Immunemonitoring,Proliferationassay,T-cellexpansion
Indication(s)/Topic(s):SESAMESyndrome,Hereditarydisease
DeliveryTime:2-5days

PepMix™PeptidePools
Theuseofcompleteprotein-spanningmixturesofoverlappingpeptides(PepMix)isextremelyefficientforimmunostimulationofT-lymphocytesanddiagnosticapplications.InordertoestablishreliableandvalidatedT-cellassayssuchasELISPOT,appropriatepositiveandnegativecontrolsareessential.Selectionofsuchcontrolshelpstoconfirmproperfunctionalityoftheassayaswellasviabilityofthecellsused.Inaddition,highqualitycontrolsaremostimportanttoestablishstandardizedassayprotocolsinclinicalsetups.Comparedtocommonlyusedcontrolslikephytohemagglutinin(PHA)andconcanavalinA(ConA)thatstimulateT-cellsaswellasothercelltypesorfulllengthantigens,syntheticpeptidepoolsoffertheadvantageofahighbatch-to-batchreproducibility,applicabilityofreliablechemicalandbiochemicalQC/QAmeasuresandshelfstabilitywhenstoredasfreezedriedaliquots.

BenefitsofPepMix™
-EquivalentorbetterstimulationofCD4⁺andCD8⁺T-cellresponsescomparedtowholeproteinantigens
-SimultaneousdetectionofCD4⁺andCD8⁺responsesinasinglesample
-ImprovedresponsesinstoredbloodandPBMcellscomparedtowholeproteinantigens
-Morereliableascontrolthanphytohemagglutinin(PHA)andconcanavalinA(ConA)
-High-batch-to-batchreproducibility
-Reliablechemicalandbiochemicalqualitycontrolandqualityassuranceforpeptidesynthesisandpeptidepoolgeneration
-Prolongedshelfstabilitywhenstoredfreezedried

PepMix™Human(Kir4.1)

SelectedReferences
"InVitroStudiesoftheImpactofMaribavironCMV-SpecificCellularImmuneResponses"
Stacheletal.,JClinVirol. (2015)-PMID:26780109
"InductionOfBroad-basedImmunityandProtectiveEfficacybySelf-amplifyingmRNAVaccinesEncodingInfluenzaVirusHemagglutinin"
Brazzolietal.,JournalofVirology (2015)-PMID:26468547
"TargetingofNucleoproteintoChemokineReceptorsbyDNAVaccinationResultsinIncreasedCD8+-mediatedCrossProtectionAgainstInfluenza"
Baranowskaetal.,Vaccine(2015)-PMID:26387432
"CharacteristicsofImmuneMemory10-15yearsAfterPrimaryHepatitisBVaccination"
Hummeletal.,Vaccine(2015)-PMID:n.a.
"TCellsSpecificforDifferentLatentandLyticViralProteinsEfficientlyControlEpstein-BarrVirusTransformedBCells"
Nowakowskaetal.,Cytotherapy(2015)-PMID:26276009
"High-densityPrecultureofPBMCsRestoresDefectiveSensitivityofCirculatingCD8TCellstoVirus-andTumor-derivedAntigens"
Wegneretal.,Blood(2015)-PMID:26024876
"MetabolicRegulationofHepatitisBImmunopathologybyMyeloid-derivedSuppressorCells"
Pallettetal.,NatureMedicine(2015)-PMID:25962123

ApplicationNotes
"DevelopingMulti-HIVAntigenSpecificT-CellsasaComponentofaCureStrategy"
Lametal.(2015)Fulltext
"Peptide-stimulatedExpansionofVirus-specificTcellsForPreventativeTreatmentAfterAllogeneicStemCellTransplantation"
Garyetal.(2015)Fulltext

Testimonials
"Toestablishanovelroleformyeloidderivedsuppressorcells(Pallettetal,Nat.Med.2015)inchronicviralinfection,weutilisedthePepMixCEFPool(extended)aswellasacustomsynthesizedPepMixspanningthecoreregionofHBVgenotypeD.Whereas,theCEFpeptidepoolconsistsof32peptides,eachcorrespondingtoadefinedHLAclassI-restrictedT-cellepitopefromCytomegalo,Epstein-Barr,andInfluenzavirus,thelattercustomPepMixincluded15mericpeptidesoverlappingby10aminoacids.SpecificallythiscompositionenabledustomonitorboththeantiviralCD8+andCD4+TcellresponsesinchronicHBVinfectionandthenon-antigenspecificTcellsthatareknowntomediateimmunopathologyintheliver.OurentireexperiencewithJPT,fromordering/deliverytouseinthelabwasexcellent.Notonlywerethereagentsabletoperformreliablyandconsistentlyinvitrofrombatchtobatch,thecustomerandtechnicalsupportprovidedwascontinuallyavailableandefficientwhenneeded.JPTwillremainour"go-to"companyforpurchasingpeptides."
Dr.LauraJPallett,InfectionandImmunity,UniversityCollegeLondon,UK